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ABSTRACT
One conclusion from the knowledge-based view is that firms develop
knowledge from experience. This paper examines the conditions under
which firms’ R&D experiences might have stronger or weaker effects on
innovation capabilities. We posit that any potential benefit depends on
the nature of this experience. In particular, we look at how technological
area experience and experience diversity affects innovation capabilities.
We further propose that, in order to leverage their experience, firms
need to consider how the interactions of technological area experience
and experience diversity affect performance. To test this model, we draw
on a data set of 3034 drug development projects undertaken by 30
large pharmaceutical companies between 1980 and 2008.
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1. Introduction
Firm-level knowledge development and its relationship to organisational performance has become
one of the dominant themes in the strategic management literature (Grant 1996; Spender 1996).
The knowledge-based view (KBV) of the firm holds that firms develop knowledge from experience
and stresses the importance for firms to create value from the effective use of experiential knowledge
(Grant 1996). Relatively unexplored in the KBV literature is an examination of how different sources/
types of experience explain variation in firms’ knowledge development (Macher and Boerner 2012).
Still more theoretical and empirical development in this area is needed to expand the knowledge-
based theory of the firm.
Studies on innovation have traditionally appealed to factors in either the industry or in the firm.
Studies in industrial economy explain innovation performance in the firm by appealing to external
and internal factors of the firm (e.g. Souitaris 2002; Vega-Jurado et al. 2008). The present study
focuses on factors within the firm. In particular, we explore differences in innovation capabilities
within and across firms. These capabilities are narrowly connected to the organisation’s ability to
develop and transfer knowledge. Innovation capabilities (i.e. rates of project success and failure)
are at the core of an organisation’s competitive advantage. We develop our theory in the context
of the biotech and pharmaceutical industry, in which new product introduction is critical to the sur-
vival of firms. Under these circumstances firms in the biotech and pharmaceutical industry are under
great pressure to increase their success rate while minimising the cash burn experienced due to
failing projects (Garnier 2008).
Working from previous research (Macher and Boerner 2012; Nickerson and Zenger 2004), we assume
that in the context of innovation firms create valuable knowledge from their experiences in dealing with
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previous problematic tasks. This understanding of knowledge formation is particularly prominent in the
context of the biotech and pharmaceutical industry, given the high levels of uncertainty surrounding the
drug development process in this industry (Kaitin and DiMasi 2011). Depending on the characteristics of
the problem or task, particular prior experiences are considered to be superior to others (Macher and
Boerner 2006). We make a contribution to this area of research by examining the interactive effects
that technological area experience and experience diversity have on innovation performance.
We make a number of contributions to the KBV literature. We are the first to study the interactive
effect of specific technology area experience and experience diversity on innovation performance. Fol-
lowing other previous works, we understand technology area experience as the level of expertise an
organisation has in given domain (Macher and Boerner 2012). Experience diversity refers to the extent
to which a firm’s technology experience is diversified across different technology areas (Breschi,
Lissoni, and Malerba 2003; Gambardella and Torrisi 1998; Xu 2015). In particular, we find that firms
can only fully benefit from their technology area experience when combined with experience diversity.
Furthermore, we posit that only focusing on technology area experience fails to fully account for the role
of experiential learning in innovation. We therefore supplement already existing work on the role of
experience in innovation performance (Macher and Boerner 2012) by suggesting the relevant conceptual
addition of the interaction between technology area experience and experience diversity to theory. We
also employ a more comprehensive understanding of innovation performance and not only consider
drug development projects that are successful but also take into account those that are terminated.
We therefore supplement the existing literature by adding empirical research on the consequences
that experience has on future rates of failure. This is in line with recent work on the importance of
failure in the context of knowledge development (Madsen and Desai 2010; Muehlfeld, Rao Sahib, and
Van Witteloostuijn 2012; Su and McNamara 2012). We also contribute to the already existing work on
drug development which has received substantially less attention than drug discovery (Cockburn and
Henderson 2001), even though the costs of development are substantially higher than those of discovery.
2. Theory and hypotheses
2.1. Technology area experience
Experience in a technological area can lead to developing skills that might be relevant to future-related
tasks. The ability to evaluate and develop future projects is largely a function of the level of prior experi-
ence relevant to the project in question. For example, prior experience in similar acquisitions can
explain the performance of future ones (Haleblian and Finkelstein 1999; McDonald, Westphal, and
Graebner 2008), or firms’ efficiency in absorbing partner’s relevant knowledge in alliances (Reuer,
Zollo, and Singh 2002). As they gain experience, firms obtain a better understanding of task require-
ments which allows them to develop a transactive memory system that helps transfer expertise
from one task to another similar task (Argote and Ren 2012; Gino et al. 2010). As a firm increases its
experience in one area, it also increases the smoothness and the ease with which it transfers its knowl-
edge to similar tasks. In line with this idea of transactive memory, a firm’s technology area experience
determines the amount of expertise it has in the area relevant to the project (Schilling et al. 2003).
Technology area experience will determine how the organisation sees a project developing in the
future and will ultimately affect the firm’s ability to predict possible problems, its confidence regard-
ing the project’s potential and its belief in its own ability to complete the project successfully. Firms
with higher levels of specialisation in technology area will deepen their ability to resolve complex
problems, attain higher levels of insights for future innovation developments (Boh, Evaristo, and
Ouderkirk 2014; Lettl, Rost, and von Wartburg 2009) and increase the performance of their R&D alli-
ances (Ernst, Lichtenthaler, and Vogt 2011). It allows firms to draw on relevant examples that they
have experienced in the past, and help them predict the course of action and potential problems
for new tasks (Ericsson and Charness 1994). Under these circumstances, firms can draw meaningful
comparisons between current tasks and similar previous tasks (Thompson, Gentner, and Loewenstein
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2000), resulting in an improvement in their overall innovation performance. We expect firms with
greater levels of technology area experience to obtain superior innovation performance in compari-
son to firms with less experience. We examine the following hypothesis:
Hypothesis 1a: Firms with greater technological area experience have higher rates of drug development success
than firms with less experience. ceteris paribus
Hypothesis 1b: Firms with greater technological area experience have lower rates of drug development termin-
ation than firms with less experience. ceteris paribus
2.2. Technology experience diversity
Experience diversity refers to the extent to which a firm’s technology experience is diversified across
different technology areas (Breschi, Lissoni, and Malerba 2003; Gambardella and Torrisi 1998). In the
literature we find evidence that suggests that knowledge and technology development benefits from
diversity due to economies of scope and KBV (Almeida and Phene 2004; Granstrand 1998). Technol-
ogy experience diversity improves a firm’s ability to develop innovative knowledge through the com-
bination of various different technologies (Boh, Evaristo, and Ouderkirk 2014; Granstrand 1998). Other
studies connect organisation survivability to their ability to develop diversified technology portfolios
(Suzuki and Kodama 2004) or the diversity of their new technology areas searches (Jiang, Tan, and
Thursby 2011). What these studies show is that having a diverse technology portfolio will allow
firms to develop new knowledge from innovative breakthroughs due to their enhanced ability to
draw from experiences across different areas of expertise. Also, having a larger stock of technology
development capabilities allows firms to increase the possibility of creating new combinations
leading to novel ideas (Fauconnier and Turner 1998) or more effective strategic alliances (Lin
2011). Another advantage of technology experience diversity is knowledge spillovers among differ-
ent units leading to a more efficient knowledge development than those firms with less diversified
experience (Almeida and Phene 2004; Laursen and Salter 2014).
Studies on teamperformance suggest that when a team involved in project development has highly
diversified past experience it brings the product from concept to market more efficiently (Buyl et al.
2011; Clark and Fujimoto 1991; Faems and Subramanian 2013; Garvin 1988). This is because more het-
erogeneous past experience results in an increased ability to make good decisions regarding future
research or development processes (Cohen and Levinthal 1990; Wei and Wu 2013) and because firms
with less diversified experience risk entering competency traps that can result in delays in development.
In other words, experience diversity helps overcome organisational inertia (Wang and Chen 2010).
Organisationsmaybecomefixed in theirwayof interpreting tasks, and that as things change, the organ-
isation will fail to respond adequately due to competency traps (Leonard-Barton 1992; Levitt and James
1988) andmay end up using knowledge gained in the past evenwhen it is not appropriate, thus result-
ing in negative performance. We discuss the following hypotheses.
Hypothesis 2a: Firms with greater technology experience diversity have higher rates of drug development success
than firms with less experience diversity. ceteris paribus
Hypothesis 2b: Firms with greater technology experience diversity have lower rates of drug development termin-
ation than firms with less diversity. ceteris paribus
2.3. Interaction between technology area experience and experience diversity
The above discussion leads us to the conclusion that organisations can improve their innovation per-
formance by means of their experience in a particular technological area and the diversity of their
overall experience. Other studies in the areas of organisational learning (Wang and Chen 2010)
and knowledge search (Laursen and Salter 2006) have also highlighted the importance of both
elements in developing innovation capabilities An important question is whether these two
aspects of an organisation’s past experience are distinct, or whether they interact with each other;
and if they interact, what sort of interaction exists between them. In this section, we argue that
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the full extent to which technology area experience and diversity affect performance depends on the
interaction between these two factors. We maintain that they are at once conceptually different and
narrowly interconnected and that one cannot be understood without the other if we really want to
get a clear picture of how experience affects knowledge development.
The learning curve literature shows that organisations vary considerably in the rates at which
their technology area experience affects performance. Equal increases of technology area experience
might affect organisational performance differently. Past research has found that differences in
development rates is a function not only of differences in the product, but also of differences in organ-
isations. There is evidence to suggest that there is oftenmore variation across organisations working on
the same area than within an organisation producing different products (Argote, Beckman, and Epple
1990). For example, in shipbuilding during the Second World War, there was a greater variation in per-
formance with the increase of technology area experience within production programmes than
between programmes (Searle 1945). Factors found to condition such variation include the possibility
of differences in organisational forgetting rates (Besanko et al. 2010) and employee turnover (Erden,
von Krogh, and Nonaka 2008). Another factor connected to this variation is an organisation’s ability
to transfer knowledge from other areas of expertise within the same organisation (Argote, Beckman,
and Epple 1990).
We argue that organisations with greater experience diversity have access to a greater range of
knowledge (which can be transferred to a new area) than organisations with a more homogenous
base. What we suggest here is that if two organisations have the same amount of technology area
experience, but one of them has higher levels of experience diversity, the one with more diversity
will have a richer variety of examples from which to draw knowledge for the task in question. In
this respect, we expect experience diversity to help explain differences in the impact of technology
area experience on innovation performance across organisations. Firms with equivalent levels of
technology area experience but with different levels of experience diversity might have different
rates of learning, resulting in variance in innovation performance.
Some sections of the literature suggest that high levels of technology area experience may
increase the risk of an organisation’s failure to appreciate the unique aspects of the project in
question, as it may be ‘blinded’ by schemas transferred from similar projects (Baum and Ingram
1998; Kahneman 2003). In order to avoid falling into narrow framing, an organisation needs to
keep a certain level of openness while increasing its experience in the task. Experience diversity
may help keep a healthy level of vigilance in the organisation when dealing with highly familiar
projects. Experience in dealing with a variety of tasks may prevent excessive technology area
experience from leading to narrow framing and a decrease in performance. On the contrary, high
levels of technology area experience in the presence of past experience diversity should allow
an organisation to fully benefit from its expertise in the task. In addition, and in the context of
external knowledge search, we find evidence that combining depth and breadth of knowledge
can improve innovation performance (Laursen and Salter 2006). The above leads to the following
two hypotheses:
Hypothesis 3a: The effect of technology area experience on rates of drug development success is positively mod-
erated by firm’s experience diversity. ceteris paribus
Hypothesis 3b: The effect of technology area experience on rates of drug development termination is negatively
moderated by firm’s experience diversity. ceteris paribus
3. Methods
3.1. Research setting
The pharmaceutical industry offers fertile ground for answering our research question. Efficiently
responding to new advances and developments is crucial as companies face tremendous pressures
to innovate. Given the low probability of a product reaching the market, ranging between 16% and
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19% (DiMasi et al. 2010) and the decline in R&D productivity (Bradfield and El-Sayed 2009), a critical
factor for managers is to allocate R&D resources wisely. In this context, leveraging past experience for
drug development is of vital importance for the pharmaceutical industry, as it will inform decisions
regarding costly project development.
3.2. Sample and data
In order to overcome a potential bias that could arise from using firms with few projects in their port-
folio, we identified 30 global pharmaceutical and biotech companies with at least 24 projects in their
portfolios (Table 1). We decided to limit the sample to firms with at least 24 projects in order to be
able to explore changes in past experience diversity. Each firm in the sample has an average of 100
active projects over the study period (1980–2008), with some having as many as 400. The diversity
variable would lose its explanatory potential in cases where firms had been involved few projects
in the past. This resulted in a sample of 3035 projects that were divided into three categories: termi-
nated, approved and active. Of these 3035 projects, 348 were successfully launched, 2528 were
ceased and 159 were still active by the end of the study period. The projects in the sample are
also distributed across 17 different therapy areas. The starting dates of all the projects in this
study range from 1980 to 2008. We used 1980 as the starting point for the study period because
it was the year in which the commercialisation of biotechnology occurred.
For all these firms we used Pharma Projects. Pharmaprojects is a Pharmaceutical Research and
Development Pipeline Intelligence database. The database contains both published and unpublished
information on pharmaceutical projects based on company questionnaires, Securities and Exchange
Commission (SEC) and Food and Drug Administration (FDA) filings, journals, annual reports, industry
conferences and press releases among others. Pharmaprojects staff attend international meetings to
Table 1. List of pharmaceutical and biotech companies in the data set.
Company Country Total Revenues (USD millions)
Pfizer USA 67,809
Novartis Switzerland 53,324
Merck & Co USA 45,987
Bayer Germany 44,200
GlaxoSmithKline UK 42,813
Johnson and Johnson USA 37,020
Sanofi France 35,645
Hoffmann–La Roche Switzerland 33,547
AstraZeneca UK 26,475
Abbott Laboratories USA 22,476
Bristol-Myers Squibb USA 17,914
Eli Lilly and Company USA 15,691
Astellas Japan 14,268
Boehringer Ingelheim Germany 13,284
Schering-Plough USA 10,594
Wyeth USA 10,378
Takeda Pharmaceutical Co. Japan 10,284
Johnson & Johnson USA 9284
Mitsubishi Tanabe Pharma Japan 8964
Nycomed Pharma Switzerland 7631
Daiichi Sankyo Japan 6298
Teva Israel 5798
Shionogi Japan 5298
Solvay Belgium 4798
Eisai Japan 4298
Dainippon Sumitomo Pharma Japan 3798
Servier France 3298
Kyowa Hakko Kirin Japan 2798
Mitsubishi Tanabe Pharma Japan 2298
Gedeon Richter Hungary 1798
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obtain information directly from research scientists. They also scan conference proceedings and the
scientific and medical literature to track new products.
3.3. Estimation procedure: competing risk
We use competing risk analysis as the best possible method when the dependent variable combines
the probability of, and the time to, a focal event. Drug development projects are at risk of being
approved or terminated. Because both outcomes are mutually exclusive, we use competing risk to
model them. Our model calculates the cumulative incidence rate of each project making the tran-
sition to either approved or terminated. This transition is captured by the instantaneous transition
rate r, defined by
rk(t) = lim
Dto
Pr (t ≤ T , (t + Dt), D = kT ≥ t)
Dt
,
where k represents one of the two possible outcomes in D. The variable Tmeasures the time spent at
risk of making one of the two possible transitions during the time interval from t to (t + Δt),
conditional on the project being at risk of making a transition at time t. This rate can be inter-
preted to mean that the variable of interest leads to a faster (slower) occurrence of the event.
Higher (lower) incidence rates suggest a larger (smaller) number of such events within a given
time period.
3.4. Dependent variables
Similar to previous work in the pharmaceutical industry (Cockburn and Henderson 2001; Danzon,
Nicholson, and Pereira 2005; Macher and Boerner 2012) we explore drug development performance
as an indicator of innovation performance. While these studies specify drug development perform-
ance as either drug development approval or drug development submission time, we employ com-
peting analysis and understand performance as the combination of rates of development approval
and rates of drug development termination. Our dependent variable not only takes into consider-
ation those drugs development projects that are successful but also those that fail. By taking into
account failure we acquire a more comprehensive understanding of innovation. The incidence
rate for drug approval indicates the number of projects that are expected to be approved over
the period of one day (as days are the time unit employed in this study). Similarly, the rate of
drug termination indicates the number of projects that are expected to be terminated over the
period of one day. As it is the norm with competing risk analyses we report the coefficients that cor-
respond to the incidence rates.
3.5. Independent variables
3.5.1. Technological area experience
Drug development projects are divided into different technology areas via therapeutic areas. We
employ this classification to create our technology area experience variable. Prior experience in a
certain therapeutic area is vital when developing future similar drug developments. As this experi-
ence grows firms develop deep expertise in the therapeutic area in question. TA experience in this
study is measured by:
TA experiencei,j,t = 100× timei,j,tTimei,t ,
where timei,j,t represents the total number of days that firm i spent in therapeutic area j at time t, and
Timei,j,t represents the total number of days that firm i spent across all therapeutic areas that it was
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engaged with at time t. This measure represents the level of familiarity that a firm would have with a
given project’s main therapy area in comparison to the firm’s overall experience across all areas.
3.5.2. Experience diversity
In order to understand differences in firms’ past experience, we use the entropy measure of diversity
as it is defined in the diversification literature (Palepu 1985). The entropy measure compares very well
with other measures of diversity (Amit and Livnat 1988; Farjoun 1998; Jacquemin and Berry 1979;
Palepu 1985). The entropy measure only uses the time spent by firms in each therapy area in its com-
putation. The less a firm’s time is dispersed across different therapy groups, the higher the related
component of the entropy measure is. We use the number and types of therapy codes in which
firms have operated and the distribution of firms’ time across these codes to create a measure of
diversification. Let EMD be the entropy measure of diversification. This arises out of operating
across several therapy areas. EMD is defined as
EMD =
∑M
j=1 P
j1n
1
Pj
( )
,
where Pj is the share of the jth therapy area in the total time invested by the firm in all projects. Note
that EMD is the weighted average of the diversification within all the M therapy areas. Each therapy
area receives a weightage equal to its share, which provides a measure of its importance within the
total operations of the firm. This expression calculates the share of each therapy area in the total time
invested by the firm in all areas.
3.6. Control variables
We include several control variables at the firm and drug level. Firm age and size affect rates of drug
approval and termination. Younger firms might not benefit as much from their experience as older
ones do, but older firms might become stagnant and inertial resulting in decreased performance
(Carroll and Hannan 2004). Also larger firms might find it more difficult to adapt to changes in the
industry due to higher levels of bureaucratisation than smaller firms. Originator captures 29
dummy variables, one for each firm in the sample, and controls for the above concerns and firm-
level heterogeneity. At the firm level we also look at the number of other projects active in the
firm as this will affect to what extent a given project needs to compete for resources. We code
this as pipeline density reflecting the level of competition for resources at the project level. This
control variable indicates the number of projects active in a firm at any one time averaged by the
number of other projects that the firm has developed to date. We average by the number of
other projects that the firm has developed to date in order to make it proportional to the size of
the firm. Similarly, we also control for the total number of other projects in the industry, as the prob-
ability that a project is approved or terminated might depend on the number of other projects
seeking approval from the FDA. Furthermore, the information that firms gather from external projects
might affect decisions regarding their own drug development projects.
We also include drug compound-related information in our analysis. Some drugs have more
pharmacological indications than others. In projects with more indications, scientists are able to
leverage knowledge more readily since many of the indications share biological processes and/or
target molecules that are common across many indications. Thus, the organisation may obtain
more useful information for testing new compounds from projects with a greater number of indi-
cations, which enhances project performance. We created pharmacology indications as a variable
indicating the number of different pharmacological codes concerning each project. Some of the pro-
jects might have up to 20 pharmacology indications, while others only have 1. At the compound level
we also included therapeutic area. The characteristics of therapy areas to which a project belongs may
affect the outcome of the project (Danzon, Nicholson, and Pereira 2005; Macher and Boerner 2006).
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We created 16 dummy variables that represent the main therapy area to which each project belongs.
We also control for project governance. We created the variable solo to capture whether a project is
conducted solo or in collaboration with another firm as it can affect the level of support for a project.
We coded the governance type of each drug development project with ‘1’ for solo projects and ‘0’ for
those conducted in collaboration with another firm. We would expect that solo projects would take
longer to complete than those conducted in collaboration with another organisation. We also control
for unobservable year effects and for right truncation with a dummy variable for the year the project
was initiated. This variable accounts for the expectation that projects starting later in the study period
are less likely to lead to approval (or termination) outcomes (Hoang and Rothaermel 2010).
4. Results
In Table 2, we present the descriptive statistics of the variables and bivariate correlation matrix. The
average proportional hazard rate for project approval is .000022. For terminating a project, the pro-
portional hazard rate is .00015. We observe a moderately high correlation between technology area
experience and experience diversity (−0.22, p < .001), which indicates that an increase in technology
area experience is associated with a decrease in experience diversity. We also find that the correlation
between project year and industry density is very high (r = 0.96, p < .001). One reason for the high
correlation could be that the number of projects active in the industry has increased progressively
over time. A reason for multicollinearity in time series data like the one employed in this work is
that regressors included in the model share a common trend, that is, they all increase or decrease
over time.
Thus, the high degree of correlation between project year and industry density may be due to
both growing at more or less the same rate (Gujarati 1988).
In Table 3, we present the results predicting project performance. Model 1 (drug approval) and
Model 2 (drug termination) include the baseline estimations containing project-level and firm-level
controls. In Model 3 (drug approval) and Model 4 (drug termination), we entered the explanatory vari-
ables of technology area experience and diversity and in order to test for Hypotheses 1a, 1b, 2a, 2b. In
Models 5 and 6, we added a two-way interaction effect that allows us to test Hypotheses 3a and 3b.
In Hypothesis 1a, we suggest that an increase in technology area experience will result in an
increase in the rate of project success. Contrary to what we state in our hypotheses the results in
Models 3 suggest that task experience negatively affects the rate for drug approval. The above
rules out what was suggested in Hypothesis 1a. In Hypothesis 1b, we predicted the relationship
between technology area experience and the probability of drug development project termination
to be negative. Our findings do not support this hypothesis. The results in Model 4 suggest that tech-
nology area experience is positive and significant. This indicates that an increase in area technology
experience would increase the incidence rate for drug termination.
In Hypothesis 2a, we suggest that the relationship between experience diversity and the prob-
ability of drug development project success is positive. In model 3 the linear term is both positive
and significant, which indicates that as diversity increases the incidence rate for approval increases.
These findings support our hypothesis. In Hypothesis 2b, we stated that the relationship between
experience diversity and the probability for drug development termination is positive. In model 4,
the linear term for experience diversity is negative and significant, which indicates that as firms
increase their experience diversity their rate of drug development termination decreases. This
finding also supports our hypothesis.
In Hypothesis 3a, we suggest that the effect of technology area experience on rates of drug devel-
opment success is moderated by firm’s experience diversity. Results in model 5 suggest that high
levels of experience diversity and technology area experience have a positive impact on performance
by increasing the incidence rate for project success. This finding supports Hypothesis 3a. With respect
to Hypothesis 3b, our results show that high levels of technology area experience in the presence of
high experience diversity has a negative impact on the rate of project termination (model 6).
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Table 2. Descriptive statistics and bivariate correlation matrix.
Mean Std. Dev. Min Max 1 2 3 4 5 6 7
1. Pharmacology indications 1.489292 1.02834 1 20 1
2. Project governance 0.8537068 0.353458 0 1 −0.2401 1
3. Project year 06-Jul-87 4.56 05-Jan-80 30-Dec-94 0.0046 0.0581 1
4. Pipeline density 88.17265 88.01513 0 421 −0.059 0.0984 0.5199 1
5. Industry density 1458.86 804.9905 0 2702 0.0087 0.0554 0.9962 0.5214 1
6. Experience diversity 0 0.174878 −1.0718 0.3029456 −0.0109 0.0025 0.0311 0.2486 0.0245 1
7. Technological area experience 0 0.084553 −0.12868 0.439099 −0.058 0.0544 −0.0211 −0.0159 −0.0216 −0.221 1
Notes: N = 3034. Bold indicates pair-wise correlation significance at 0.05 level.
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Table 3. Results predicting drug approval and drug termination.
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Drug approval Drug termination Drug approval Drug termination Drug approval Drug termination
Therapeutic area Included Included Included Included Included Included
Originator Included Included Included Included Included Included
Pharmacology indic. .22498569*** −.5190908*** .19772511*** −.49715294*** .20084038*** −.49622625***
0.03505008 0.04694727 0.03486826 0.04894738 0.03576313 0.04889022
Project governance −2.2060261*** 2.193808*** −1.8793259*** 2.1037333*** −1.8738138*** 2.1061251***
0.14000148 0.12464794 0.14082475 0.14148698 0.13923479 0.14133402
Project year −.00166941*** .0010114*** −.00157561*** .00111995*** −.00151281*** .00109859***
0.0003936 0.00017425 0.00039379 0.00017322 0.00039602 0.00017301
Pipeline density 0.00120478 −0.00025713 0.00163911 −.00253645*** 0.0020721 −.00259506***
0.00209148 0.00053828 0.00207077 0.00054882 0.00209796 0.00056228
Industry density .00311051*** −.00097802** .00287279*** −.00073507* .00270282*** −0.00067789
0.00079309 0.00036109 0.00078801 0.00035219 0.00079572 0.00035122
Experience diversity 27.765973*** −21.467324*** 31.906205*** −22.127265***
6.0677292 1.2564302 6.4788208 1.2908379
Technological area experience −2.5099478* 2.0175919*** −1.2618811 0.33435193
1.2120301 0.43318609 1.3442073 0.59207944
Exp. diver. × techn area exp 15.911276*** −5.2839825***
4.1179251 1.3090883
Wald Chi square 863.98*** 1520.54*** 904.91*** 1649.85*** 900.17*** 1693.26***
Log pseudolikelihood −2339.7694 −17022.103 −2312.9529 −16614.897 −2305.3612 −16601.104
Note: N = 3034.
†p < 0.1.
*p < .05.
**p < .01.
***< .001.
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5. Discussion
Our findings support the assumption that more experience is always beneficial as enhances learning-
by-doing and decision-making (Grant 1996), economies of scale (McDonald, Westphal, and Graebner
2008) or expertise (Leonard-Barton 1992). Even though our findings support the above assumption,
they also qualify how this assumption should be understood.
First, and contrary to what other studies suggest (Macher and Boerner 2012), our findings indicate
that the relationship between technology area experience is not unambiguously positively correlated
with performance. Our results show that as technology area experience increases, the rate at which
projects are approved diminishes, while the rate at which projects are terminated increases. This
suggests that high levels of technology area experience can prevent a firm from making the appro-
priate inferences from what has been learnt. These findings are in line with some other findings in the
literature suggesting that high levels of technology area experience could lead to a decrease in per-
formance due to narrow framing (Kahneman 2003). The rationale maintains that high levels of tech-
nology area experience could lead to inadequate framing of new projects and therefore result in
negative knowledge transfer that can affect the firm’s ability to commercialise new knowledge.
We understand that a high level of technology area experience can be a consequence of a mostly
exploitative strategy. Exploitation favours engagement in n areas in which the organisation is
already experienced (March 1991). As consequence our findings could also be interpreted as
suggesting a negative relationship between exploitation and performance.
Our findings that diverse experience leads to superior performance support other works in the
field. In particular, they are in line with other work on project development that suggests diversifica-
tion helps innovation performance (Clark and Fujimoto 1991; Garvin 1988; Melero and Palomeras
2014; Østergaard, Timmermans, and Kristinsson 2011). Experience diversity, as suggested in this
article, allows a firm to keep the sense of a situation open; this is certainly an advantage in the
context innovation in the pharmaceutical industry, in which managers and scientists are constantly
facing novel problematic situations. Even though our findings support the idea that diversity leads to
openness when dealing with novel problems (Cohen and Levinthal 1990), we also acknowledge that
achieving diversity of experiences might be negatively affected by factors like an overly strong
emphasis on appropriability (Laursen and Salter 2014). As argued with technology area experience,
we suggest that our findings also have implications for research on exploration and exploitation. A
diverse experience can be seen as a consequence of explorative strategies, which would suggest
that our findings indicate a positive relationship between exploration and performance.
A crucial outcome of this paper relates to findings in the literature suggesting that there is often
more variation across organisations working on the same technology area than within an organisation
producing different products (Argote, Beckman, and Epple 1990). Our findings suggest that one factor
that explains why the same level of technology area experience might lead to differences in perform-
ance reflects variation in experience diversity. As a result we maintain with other studies in the field that
technology area experience and experience diversity are narrowly connected and need to be studied
together in order to really understand what effect experience has on innovation (Boh, Evaristo, and
Ouderkirk 2014; Laursen and Salter 2006). In particular, our findings support other studies that maintain
that achieving depth and breadth of knowledge enhances innovation performance (Laursen and Salter
2006). The results of our study show that when an increase in diversity is accompanied by an increase in
technology area experience, the firm will benefit from an increase in the rate at which projects are
approved. This suggests that the negative impact on the rate of drug approval that we found was
associated with increases in technology area experience will vanish when combined with an increase
in diversity. This supports the idea that technology area is only damaging to a firm’s innovation per-
formance when the firm has a limited variety of knowledge that it can refer to when working on
new projects’. In other words, real damage to innovation performance does not result from technology
area experience itself, but from high levels of technology area in the absence of expertise in other areas.
An increase in technology area experience is not harmful if a firm combines it with experience in other
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areas. The danger of narrow framing posed by high levels of technology area experience vanishes when
a firm has been exposed to a variety of other areas.
This work has certain limitations. First, we conduct our research in single industry. This is a limit-
ation for the generalisation of our findings. A more complete picture would consider other industries.
Second, further research in the area may wish to consider conceptualising technology area experi-
ence and experience diversity differently. Although we employ well-established and tested measure-
ments, it would beneficial for the generalisation of findings to explore how other measurements of
the explanatory variables compare to the ones employed here. Third, due to data limitations, we
examine only drug compounds developed by 30 large pharmaceutical companies. Even though
our sample is large enough to yield valid results, it would be more informative if we could
conduct the same study on a larger and more diverse firm sample. Fourth, drivers of innovation
are various and our study does not directly addresses factors like non R&D variables (Hervas-
Oliver, Garrigos, and Gil-Pechuan 2011) or the acquisition of new equipment (Hervas-Oliver,
Sempere-Ripoll, and Boronat-Moll 2014) that have been proven to be relevant in this context.
6. Conclusion
This essay elucidates how experience explains difference in innovation capabilities within and
between firms. Several contributions at the theoretical level to existing KBV research are proposed.
We find that both technology area experience and experience diversity have performance impli-
cations, which adds to the KBV research that examines boundary decisions. Both, technology area
experience and experience diversity are found to have important performance effects. Technological
area experience facilitates knowledge development through experiential learning-by-doing and
experience diversity through spillovers. Furthermore, we suggest that firms can only fully realise
the potential of their technology area experience when combined with a wide enough base of experi-
ence diversity. If technology area experience is not accompanied by experience diversity then firms
are at risk of incurring negative knowledge transfer and narrow framing. We, therefore, argue that
technology area experience and experience diversity are important and interdependent determi-
nants of firms’ ability to correctly leverage their experience for better innovation. We also suggest
that both have to be considered jointly when researching the relationship between experience
and innovation performance. The importance of experience diversity that this study highlights
might also be behind the motivation for companies to enter into mergers and acquisitions; compa-
nies can expand the diversity of experiences by getting access to the experiences of other companies
in the industry. In this respect, acquiring or merging with another company is a way of widening the
experience pool of a company and by extension increasing its innovation performance.
Also future research may consider disassociating between technology area experience and experi-
ence diversity, as one of our conclusions shows that one cannot be understood without the other. We
believe that any future work that does not include both these ideas will risk obtaining spurious
results. As we show in this essay, looking at only one of these variables can lead to misleading or
incomplete results.
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